Biologics News
A Letter to Our Biopharma Clients About Organizational Changes
Valued Biopharma Partner, At Biologics by McKesson, we know that your complex, personalized therapies require customized support tailored to your unique needs. It is a privilege to serve as a partner to you in your product commercialization, collaborating to maximize...
GAVRETO™ (pralsetinib), FDA Approved for Treatment of Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer, Available at Biologics by McKesson
CARY, N.C., September 17, 2020—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been selected by Blueprint Medicines as a specialty pharmacy provider for GAVRETO™ (pralsetinib) for the treatment of adult...
INQOVI (cedazuridine and decitabine), FDA Approved for Treatment of Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia, Available at Biologics by McKesson
CARY, N.C., August 21, 2020—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been selected by Taiho Oncology, Inc. as a specialty pharmacy provider for INQOVI® (decitabine and cedazuridine) tablets for the...
A Letter to Our Customers from Our New General Manager, Brandon Tom
Valued Customers, As the new vice president and general manager of Biologics by McKesson, let me start by saying I am truly thrilled to lead this wonderful company and the amazing people who provide our services to you and your patients every day. I am also equally...
XPOVIO (selinexor), FDA Approved for Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL), Available at Biologics by McKesson
CARY, N.C., June 29, 2020—Biologics by McKesson, an independent specialty pharmacy specializing in oncology, rare diseases and other complex therapeutic areas, was selected by Karyopharm Therapeutics, Inc. as a specialty pharmacy provider for XPOVIO® (selinexor) for...
Brandon Tom Appointed New General Manager of Biologics by McKesson
CARY, N.C., June 22, 2020—Biologics by McKesson, an independent specialty pharmacy and patient services company specializing in oncology, rare diseases and other complex therapeutic areas, is pleased to announce that Brandon Tom, PharmD, was named its new general...
QINLOCK (Ripretinib), FDA Approved for Treatment of Gastrointestinal Stromal Tumors (GIST), Available at Biologics by McKesson
CARY, N.C., June 2, 2020—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, was selected by Deciphera Pharmaceuticals as a specialty pharmacy provider for QINLOCK™ (ripretinib) for the treatment of adult patients...
RETEVMO (selpercatinib), FDA-Approved for Treatment of RET-driven Lung and Thyroid Cancers, Available at Biologics by McKesson
CARY, N.C., June 1—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been selected by Eli Lilly and Company as a specialty pharmacy provider for RETEVMO™ (selpercatinib), the first drug approved by the U.S....
Pemazyre™ (pemigatinib) Available Exclusively at Biologics by McKesson
CARY, N.C., May 27, 2020—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, will be the exclusive specialty pharmacy provider for Pemazyre™ (pemigatinib), Incyte’s selective fibroblast growth factor receptor...
TRODELVY (sacituzumab govitecan-hziy), FDA Approved for Treatment of Metastatic Triple-negative Breast Cancer, Available Only at Biologics by McKesson
CARY, N.C., May 8, 2020—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, was selected by Immunomedics, Inc. as a specialty pharmacy provider for TRODELVY™ (sacituzumab govitecan-hziy) for the treatment of...